1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.

Slides:



Advertisements
Similar presentations
1 Advisory Council April 1, 2011 Child Care Development Fund – State Plan for Federal Fiscal Years 2012 and 2013.
Advertisements

1 EEC Board Meeting May 10, 2011 Child Care Development Fund – State Plan for Federal Fiscal Years 2012 and 2013.
What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Medication Management
5th Annual PBM Pharmacy Informatics Conference
MEDICINES SELECTION & FORMULARY MANAGEMENT
Section 1115 Medicaid Waiver Renewal Plan/Provider Incentive Programs Expert Stakeholder Workgroup Framing Our Discussion Wendy Soe and Sarah Brooks Department.
QI Initiatives for Psychotropic Use in Foster Youth in Maine Lindsey Tweed MD MPH Office of Child & Family Services; Maine DHHS
Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy Program Laurence H. Miller, M.D., Senior Psychiatrist.
Pharmacy Program Initiatives Threshold, Mandatory Generic, Maximum Allowable Cost (MAC) Javier Menendez, RPh Pharmacy Manager Department of Medical Assistance.
NPS is an independent, non-profit organisation for Quality Use of Medicines, funded by the Australian Government Department of Health and Ageing. Safe.
Drug Utilization Review (DUR)
The Antipsychotic Atlas Project - Overview Kennedy, J (PI); S Murphy; S McPherson & M Layton (co-Is) Start date: 9/13End date: 8/15 This research project.
1 District of Columbia Medical Assistance Administration Expedited Prior Authorization Pharmacy Guidance NOTE: As of October 1, 2008, the Medical Assistance.
Staff Health Care Committee Recommendations An update for UAA’s APT and Classified Staff Councils November 2009.
Omnibus Budget Reconciliation Act (OBRA-90) Goal To save money.
Richland County Safety Council BWC Pharmacy Program Drug Utilization Management Outcomes John Hanna, R.Ph. BWC, Pharmacy Director 7/13/2015BWC Pharmacy.
Plan Year. 2 WHAT’S NOT CHANGING FOR 2014  Premiums will remain the SAME  First Choice providers and Generic Medications are STILL NO COST TO.
© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February,
1 Public Hearings: May , 2013 Child Care Development Fund Massachusetts State Plan Federal Fiscal Years 2014 and 2015.
Presented by: Keenan & Associates Debra L. Yorba, Sr. Vice President February 22, 2014 License Plan Design Sub-Committee Recommendations KPPC/ESI.
Medicare Modernization Act, Part D Prescription Drug Benefit Presentation for County Program Administrators September 1, 2005.
© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?
Medication Access Economics: Michigan Data and Implications Howard B. Fleeter, PhD Prepared for Michigan Partners in Crisis Annual Winter Conference December.
Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Joint Commission on Health Care Patrick W. Finnerty Department.
Prior Authorization Criteria for PDL Classes: Alzheimer’s Anti-emetics High Potency Statins Hormone Replacement Therapy Multiple Sclerosis – Tysabri Charles.
Pre-Existing Condition Insurance Plan “HealthBridge NY” New York State Insurance Department Eileen Hayes Health Bureau.
A First Look at Meaningful Use Stage 2 John D. Halamka MD.
Muskie School of Public Service Institute for Health Policy Evaluating the Impact of Part D on Beneficiaries: Early Lessons Susan Payne Institute for Health.
State of New Hampshire Pharmacy Benefit Changes Effective November 1, 2011 Presented By: Melisa Briggs.
The Impact of Medicare Part D on Dual Eligible Psychiatric Patients’ Medication Access and Continuity.
Florida Agency for Health Care Administration Florida Center for Health Information and Policy Analysis Florida Public Health Association - Medical Director’s.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
Using Recent Research to Improve the Cost-Effectiveness of VA Antipsychotic Formulary Policy Robert Rosenheck MD Michael Sernyak MD New England MIRECC.
Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents Sandhya Mehta, MS; Hua Chen, MD, PhD; Michael Johnson, PhD; and Rajender R. Aparasu,
Roles of DMAS, Pharmacy & Therapeutics Committee, and Preferred Drug List Contractor Presentation to: The Medicaid Pharmacy & Therapeutics Committee Patrick.
New Zealand Pharmacy Services Andi Shirtcliffe B. Pharm, PG Dip (Clin) Pharm, Reg Pharm NZ Chief Advisor – Pharmacy, New Zealand Ministry of Health.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Evaluation of Virginia’s Preferred Drug List: 2 nd Quarter Interim Report Policy and Research Division June 22, 2004Department of Medical Assistance Services.
Treatment of Schizophrenia THE DEBATE OF THE YEAR! EFFICACY vs. TOLERABILITY: WHICH TRUMPS? POINT- COUNTERPOINT.
1 Iowa Medicaid Preferred Drug List Presented by: Timothy Clifford, MD September 28 & 29, 2004.
Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Medicaid Pharmacy & Therapeutics Committee Cynthia B. Jones.
Avalere Health LLC | The intersection of business strategy and public policy Formulary Design: Balancing Cost and Access November 1, 2005 Presented By:
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
MaineCare Policies to Prevent Pharmaceutical Waste Jennifer Palow Pharmacy Director.
Seniors’ Health Program Kevin Ring, Human Resources.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
Evaluation of Virginia’s Preferred Drug List: 4th Quarter Report Policy and Research Division November 2, 2004Department of Medical Assistance Services.
Drug Formulary Development & Management
Technology, Information Systems and Reporting in Pharmacy Benefit Management Presentation Developed for the Academy of Managed Care Pharmacy Updated: February.
Travis County HRMD FY 2012 Benefits Work Session Employee Benefits Committee HRMD Staff.
Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;
Formulary Manufacturer Contracting Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2015.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Greater Chicago Epilepsy Consumer Conference 2016
Antibiotics: handle with care!
Schizophrenia’s Heterogeneity
Health Technology Assessment
Antipsychotics: chemistry and pharmacokinetics
Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P
University of Nizwa College of Pharmacy and Nursing School of Pharmacy
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Will PBMs Participate in the New Medicare Prescription Drug Program
Pharmacy Benefit Manager
Hospital pharmacy.
Drug Formulary Development & Management
Presentation transcript:

1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives

2 PDL Preferred Drugs: By definition are usually Cost-Effective Provide the best clinical outcome for the least amount of money

3 PDL What it’s not A PDL is not a Formulary Formulary is a limited list of drugs that are covered In a PDL all Drugs continue to be covered Members have access to Non-Preferred Drugs in a variety of ways: By Prior Authorization By Step Therapy By Grandfathering in certain Drug Classes By Special Medical Conditions (Cancer)

4 Antipsychotics Nearly $20 million (state + federal) spent annually 11% of drug budget Over 12,000 users Presently, PDL only addresses high doses and duplicate therapy Can save over $1 million (state) by selecting first-line drugs that won’t need PA 15 States currently PA in this Category

5 PA for Some Atypicals Follow National Association of State Mental Health Directors Guidelines (see next 2 slides) Many choices in first line medications Established users not affected (about 50% over course of the year) Only affects new starters

6 Antipsychotic PDL: Ensuring Appropriate Access and Efficient Utilization (NASMHD) All medications should be available. Not all medications need be available on a first-line basis. PA should be simple and flexible. Choices of first-line medications at a minimum must include: Clozapine (any approved formulation) [Treatment-resistance] Risperidone or paliperidone [Atypical with long-acting formulation] Ziprasidone or aripiprazole [Weight-neutral atypical] Olanzapine or quetiapine [Sedating atypical] Haloperidol or fluphenazine [high potency typical and long- acting formulation] Perphenazine or thiothixene or other medium-potency typical Chlorpromazine or other low-potency typical.

7 Antipsychotic PDL: Ensuring Appropriate Access and Efficient Utilization (NASMHD) Helps ensure that medications are prescribed according to manufacturer indications A prescription drug may be selected for prior authorization if one of the following characteristics apply: Clinically appropriate High ingredient cost Use is within a narrow member population Drugs with a high potential for inappropriate use or abuse Agents that are best reserved for second or third line therapies

8 What happens when a PA is needed? But the doctor has not completed the PA request There was a one time override the pharmacist could use to dispense a one month supply during the PDL implementation phase. The member always has access to a 96 hour emergency supply. Nearly 80% of PA’s submitted are approved Completed PA receive a decision on average within 3 hours of submission

9 Draft PA Criteria Grandfather existing users Start of NP in Hospital setting will be grandfathered 3 week trial of an effective dose of a Preferred Drug will meet approval criteria for a NP Drug Documentation of good response to samples of NP Drug Documentation of significant side effects will meet approval criteria for NP Drug Doctor can always request a prior authorization without having to use Preferred Drug if medical necessity is documented

10 What happens when a PA is not approved? Additional information documenting medical necessity for a re-determination may be submitted. A member can appeal the decision by requesting a Fair Hearing.

11 Safety Net Protections Completed PA’s acted on within 24 hours of submission Average time to review a completed PA is 3 hours 96 hour supply of drug is available on an emergency basis

12 4 Brand Name Per Month Limit $1 Million savings (State) Only for MaineCare members who are: Not a dual eligible Over 18 years of age Will not apply to: Cancer medications HIV medications Antipsychotics Currently have 5 Brand limit for MaineCare members living in certain settings 17 States currently have limits in place